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Abstract
Background
High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate,
with prolonged survival in several malignant diseases and with the benefit of platinum-
based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in met-
astatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to
benefit of first-line chemotherapy.
Methods
Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC
patients. Kaplan-Meier analysis and Cox regression proportional hazards models were
used to access the impact of RBM3 expression on overall survival (OS) and progression-
free survival (PFS).
Results
High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic fac-
tor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50–0.90 and
HR 0.66, 95% CI 0.48–0.91, respectively). PFS was significantly longer in patients with high
RBM3 expression who had received first-line oxaliplatin based treatment, compared to
those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic
expression (p-value 0.020 and 0.022 respectively).
Conclusion
High RBM3 expression is an independent predictor of prolonged survival in mCRC patients,
in particular in patients treated with first-line oxaliplatin based chemotherapy.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in the world affecting 1.4 million
people each year [1]. Approximately 20% have metastatic CRC (mCRC) at the time of diagno-
sis and about 20% subsequently develop metastatic disease, most with incurable disease [2].
Median survival for mCRC varies between 5–6 months in untreated patients and approaches
30 months in selected groups with good performance status having received optimal treatment
[3–6]. Palliative chemotherapy aims to prolong the life of patients and ameliorate quality of
life. There is a great need to identify biomarkers that predict response to chemotherapy, in
order to save patients from affliction and contribute to better palliation. Chemotherapy for
mCRC is based on 5-fluorouracil (5-FU) with the addition of either irinotecan or oxaliplatin.
Irinotecan combined with 5-FU, as in FOLFIRI, increases progression-free survival (PFS) and
overall survival (OS) [7]. Oxaliplatin combined with 5-FU, as in FOLFOX, increases PFS and
likely also OS [7, 8]. Oxaliplatin cross-links the DNA strands and induces apoptosis [9]. Oxali-
platin works synergistically with 5-FU, probably via down regulation of thymidylate synthase
[10]. First-line chemotherapy with irinotecan based chemotherapy or oxaliplatin based che-
motherapy seem to give a similar overall survival and no data have shown preference for one
schedule over the other as first-line treatment [11].
RNA-binding motif protein 3 (RBM3) is an RNA and DNA-binding protein that in
response to various types of cellular stress, e.g. hypothermia [12], hypoxia [13], and oxidative
stress [14], is required for cell proliferation [12, 15]. Silencing RBM3 decreases the sensitivity
to cisplatin in ovarian cancer cell lines [16]. High RBM3 expression has been associated with
improved survival in a number of malignancies, e.g. breast cancer, malignant melanoma, uroe-
pithelial cancer, ovarian cancer, colorectal cancer, gastroesophageal cancer, and testicular can-
cer [16–22].
In CRC, the beneficial prognostic value of high RBM3 expression has been demonstrated in
three independent studies [19, 23, 24], mainly including patients with stage II-III disease. To
our best knowledge, the relationship between RBM3 expression and response to chemotherapy
in mCRC has not yet been reported.
Therefore, this study aimed to evaluate RBM3 as a prognostic factor in mCRC, overall and
in relation to the choice of first-line chemotherapy.
Materials and methods
Patients
Sorbye et al have previously described the cohort [4, 25] which consists of 798 patients with
unresectable mCRC diagnosed in the catchment area of the oncology units at three university
hospitals; Odense University Hospital in Denmark, Haukeland University Hospital in Norway
and Uppsala University Hospital in Sweden. All patients diagnosed with mCRC between
August 2003 and October 2006 were prospectively registered at referral or using regional can-
cer registers. Written informed consent was obtained from all participants seen at the clinics.
The intention of the cohort was to prospectively study different outcomes in an unselected
population with mCRC.
Tumour tissue microarrays (TMAs) from mainly the primary tumour (5 cases from meta-
static tissue) were constructed from 462 (58%) cases and RBM3 expression could be evaluated
in 455 (98%) of these. In the remaining cases, the material was not sufficient to take a core for
TMA, containing too much necrotic tissue to evaluate or not available [25]. A flowchart is
shown as S1 Fig. The study was approved by the ethical committees in Norway (Regional
Committee for medical and health research ethics-REC West 2009/2052), Sweden (Regional
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Tissue microarray construction
TMAs were generated for protein expression profiling using immunohistochemistry (IHC).
IHC staining, slide scanning and evaluation of outcome were performed in accordance with
strategies and standards used in the Human Protein Atlas [26, 27]. Original diagnostic tumour
blocks were used as donor blocks for the recipient TMA blocks. Representative tumour tissue
from each tumour was sampled in duplicate cores of 1 mm in diameter and assembled in the
TMAs. A corresponding haematoxylin and eosin stained section was produced from each
TMA block to control for quality and presence of tumour cells.
Antibodies
IHC was performed as previously described [27], in brief, 4 μm sections of the TMA blocks
were cut and automated IHC was performed using a Lab Vision Autostainer 480 (Thermo
Fisher Scientific). The mouse monoclonal anti-RBM3 antibody (CAB062559 / clone 0296,
Atlas Antibodies AB, Stockholm, Sweden, diluted 1:1 000) was used as primary antibody.
Analysis of immunohistochemical staining
The IHC staining was evaluated by CS and KJ, who were blinded to clinical and outcome data.
Interobserver differences were discussed in order to reach consensus. RBM3 expression was
evaluated both in the cytoplasm and in the nuclei, whereby the fraction of positive cells was
estimated, and the staining intensity denoted as 0 (negative), 1 (mild), 2 (moderate) and 3
(strong). A multiplier of fraction and intensity was constructed regarding nuclear and cyto-
plasmic expression (nuclear and cytoplasmic score), concluding a score between 0–3.
Statistical analyses
Chi square test was used to examine the associations between the nuclear and cytoplasmic
RBM3 score and clinicopathological characteristics. Kaplan-Meier and log rank test were
applied to illustrate differences in OS and PFS according to RBM3 expression. Classification
and regression tree (CRT) analysis was applied to estimate the ultimate prognostic cut-off for
the nuclear and cytoplasmic RBM3 scores, respectively. A classification based on negative and
positive RBM3 expression was also used. Cox regression proportional hazards models were
used to access the impact of RBM3 expression on OS and PFS in both univariable and multi-
variable analyses. PFS was calculated as time from start of first-line treatment until progression
or death. A P-value <0.05 was considered statistically significant. All statistical analyses were
preformed using IBM SPSS Statistics version 23.
Results
RBM3 expression in relation to patient and tumour characteristics
Among the 455 evaluable cases, 46 (10%) cases were negative for nuclear RBM3 expression
and 67 (15%) cases were negative for cytoplasmic RBM3 expression. In the remaining cases,
RBM3 was expressed in various intensities and fractions in the nuclei and/or cytoplasm. CRT
analysis determined an optimal prognostic cut off at 0.550 for nuclear RBM3 expression and at
0.025 for cytoplasmic RBM3 expression. 166 (36%) cases were denoted as having low and 289
(64%) as having high nuclear expression, and 126 (28%) cases were denoted as having low and
329 (72%) cases as having high cytoplasmic expression, retrospectively. Sample IHC images
RBM3 and metastatic colorectal cancer
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are shown in Fig 1. Associations of nuclear RBM3 expression with clinicopathological charac-
teristics are shown in Table 1, and for cytoplasmic expression in S1 Table. High nuclear RBM3
expression was statistically significant associated with BRAF wild type tumours, and RBM3
expression was significantly higher in patients who underwent secondary surgery and received
irinotecan based treatment. High cytoplasmic RBM3 expression was significantly associated
with age<75 years, BRAF wild type tumour, secondary surgery and irinotecan based treat-
ment. Positive nuclear RBM3 expression was significantly more frequent in tumours located
in the rectum, in BRAF wildtype tumours and in metachronous disease. Positive cytoplasmic
RBM3 expression was significantly more frequent in BRAF wildtype tumors, in patients who
had undergone secondary surgery and with metachronous disease.
RBM3 expression in relation to overall survival
Kaplan-Meier analyses demonstrated that high RBM3 expression was associated with a signifi-
cantly longer OS in the entire cohort, both for nuclear (Fig 2A, p<0.001) and cytoplasmic (Fig
2B, p<0.001) expression. This difference remained statistically significant also after exclusion
of cases that had received adjuvant treatment (n = 59, data not shown). Median survival was
13 months in the group with high nuclear RBM3 expression and 7 months in the group with
low RBM3 expression (p = 0.001). In the group with high cytoplasmic RBM3 expression the
median survival was 13 months and 7 months in the group with low cytoplasmic RBM3
expression (p = 0.005). Dichotomisation of RBM3 expression comparing positive to negative
expression, revealed a significantly longer OS regarding cytoplasmic expression, but not
regarding nuclei expression (S2 Fig).
As shown in Table 2, these associations were confirmed in univariable Cox regression anal-
yses (HR = 0,61, 95% CI = 0,50–0,74 for nuclear and HR = 0,61, 95% CI = 0,49–0,76 for cyto-
plasmic expression), and remained statistically significant in multivariable analyses
Fig 1. Immunohistochemical images of RBM3 staining. Representing colorectal tumours with (A) negative, (B) weak, (C) moderate and (D-F)
strong expression in a varying proportion of tumour cells. All images captured at X 20 magnification.
https://doi.org/10.1371/journal.pone.0182512.g001
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(HR = 0.67, 95% CI = 0.50–0.90 for nuclear and HR = 0,66, 95% CI = 0,48–0,91for cytoplasmic
expression). When nuclear and cytoplasmic expressions were used as continuous variables
Table 1. Associations between nuclear RBM3 expression and clinicopathological characteristics. ALP; alkaline phosphatase, CEA; carcinoembry-
onic antigen, KRAS; Kirsten rat sarcoma. (Regarding cytoplasmic expression see S1 Table).
High Expression Low expression p-value Positive Negative p-value
N (%) N (%) N (%) N (%)
Age
<75 years 198 (69) 102 (61) 0.126 271 (66) 29 (63) 0.663
 75 years 91 (31) 64 (39) 138 (34) 17 (37)
Sex
Female 141 (49) 89 (54) 0.322 202 (49) 28 (61) 0.140
Male 148 (51) 77 (46) 207 (51) 18 (39)
Performance status
0–1 199 (69) 105 (63) 0.222 274 (67) 30 (65) 0.809
>1 90 (31) 61 (37) 135 (33) 16 (35)
Primary site
Colon 213 (75) 127 (78) 0.352 300 (74) 40 (89) 0.032
Rectum 73 (25) 35 (22) 103 (26) 5 (11)
Missing 4 3 6 1
ALP μg/l
Normal 115 (46) 62 (42) 0.503 158 (44) 19 (50) 0.463
Elevated 137 (54) 85 (58) 203 (56) 19 (50)
Missing 19 37 48 8
BRAF
Wild-type 234 (83) 117 (72) 0.010 324 (81) 27 (63) 0.005
Mutated 48 (17) 44 (27) 76 (19) 16 (37)
Missing 7 5 9 3
KRAS
Wild-type 160 (57) 99 (63) 0.243 232 (58) 27 (66%) 0.349
Mutated 121 (43) 59 (37) 166 (42) 12 (34)
Missing 8 8 11 7
CEA μg/l
Normal 5 46 (28) 22 (25) 0.585 61 (27) 7 (33) 0.502
Elevated > 5 117 (72) 66 (75) 169 (74) 14 (67)
Missing 126 78 179 25
Time for metastasation
Synchronous 142 (49) 96 (58) 0.074 207 (51) 31 (67) 0.031
Metachronus 147 (51) 70 (42) 202 (49) 15 (33)
Secondary curative surgery
Yes 33 (11) 2 (1) <0.001 34 (8) 1 (2) 0.138
No 256 (89) 163 (99) 374 (92) 45 (98)
Missing 1 1
First line chemotherapy
Oxaliplatin-based 113 (39) 53 (32) 0.015 151 (37) 15 (32) 0.132
Irinotecan-based 43 (15) 17 (10) 57 (14) 3 (7)
5-FU single 27 (9) 30 (18) 47 (11) 10 (22)
Best Supportive care 88 (31) 56 (34) 129 (32) 15 (32)
Other 17 (6) 10 (6) 25 (6) 3 (7)
https://doi.org/10.1371/journal.pone.0182512.t001
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statistically significant associations, with a prolonged OS, were seen. The associations only
remained statistically significant for nuclear RBM3 expression in a multivariable analysis
(Table 2).
Prognostic value of RBM3 expression in relation to chemotherapy
Several associations were seen between RBM3 expression and PFS in strata according to high
and low RBM3 expression and type of treatment given as first-line. PFS was longer for patients
with tumours displaying high nuclear or cytoplasmic RBM3 expression who received oxalipla-
tin based treatment as first-line chemotherapy, in comparison to irinotecan based treatment
(p-value 0.020 for nuclear expression and 0.022 for cytoplasmic expression). (Fig 3A and 3B)
The median PFS was 9.35 months in the group with high nuclear RBM3 expression that
received oxaliplatin based chemotherapy and 8.80 months in the group with high nuclear
expression that received irinotecan based chemotherapy (p = 0.002). In the group with high
cytoplasmic expression the median PFS was 8.99 months in the oxaliplatin group and 8.77 in
the irinotecan group (p = 0.028).
Kaplan-Meier analysis of OS revealed that patients with tumours displaying high nuclear or
cytoplasmic RBM3 expression who received oxaliplatin based treatment as first-line chemo-
therapy had significantly longer survival compared to all other strata (Fig 3C and 3D). Espe-
cially long-term survival was increased if oxaliplatin based chemotherapy was used as first-line
treatment when RBM3 expression was high. This difference remained statistically significant
also after exclusion of patients who had received adjuvant treatment (n = 59, data not shown).
As seen in S2 Fig, positive RBM3 expression and oxaliplatin based treatment as first-line
meant a significantly longer PFS (p = 0.022 for nuclear and p = 0.030 for cytoplasmic expres-
sion) compared to irinotecan based treatment.
As shown in Table 3 and S3 Table high nuclear and cytoplasmic expression was associated
with complete or partial response to first-line chemotherapy, prolonged median PFS and initi-
ation of second line chemotherapy. Prolonged PFS was the only statistically significant differ-
ence between the groups of positive and negative RBM3 expression and was seen regarding
cytoplasmic expression.
There was a statistically significant interaction between RBM3 expression and oxaliplatin
based treatment, in relation to PFS (p = 0.047). No such interaction was seen in relation to OS
(data not shown).
Notably, there were no significant differences in PFS or OS between patients having received
oxaliplatin based treatment and those who had received other types of chemotherapy regardless
Fig 2. Kaplan-Meier estimates of overall survival. Estimates according to (A) nuclear and (B) cytoplasmic
RBM3 expression in the entire cohort.
https://doi.org/10.1371/journal.pone.0182512.g002
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of RBM3 expression (S3 Fig). Synchronous disease was associated with oxaliplatin based treat-
ment, however no other statistically significant differences regarding patient characteristics
between the oxaliplatin treated group and the irinotecan treated group were seen (S2 Table).
Discussion
Our results demonstrate that high RBM3 expression correlates with longer OS in patients with
mCRC. In patients with tumours displaying high RBM3 expression, we have also shown a
Table 2. Cox regression analysis of 5-year overall survival according to nuclear and cytoplasmic RBM3 expression. Includes the entire cohort. ALP;
alkaline phosphatase, CEA; carcinoembryonic antigen.
N (events) Univariable p N (events) Multivariable* p*
HR (95%CI) HR (95%CI)
Age
 75 years 155 (153) 1.00 65 (63) 1.00
<75 years 300 (271) 0.434 (0.35–0.53) <0.001 173 (151) 0.723 (0.53–0.99) 0.040
Sex
Male 225 (210) 1.00 116 (105) 1.00
Female 230 (214) 0.95 (0.79–1.15) 0.604 122 (109) 0.68 (0.51–0.90) 0.007
Performance status
0–1 304 (274) 1.00 186 (163) 1.00
>1 151 (150) 3.05 (2.48–3.76) <0.001 52 (51) 2.06 (1.46–2.90) <0.001
Primary site
Colon 340 (316) 1.00 174 (156) 1.00
Rectum 108 (101) 0.90 (0.72–1.12) 0.339 64 (58) 0.90 (0.64–1.27) 0.554
ALP μg/l
Normal 177 (154) 1.00 111 (92) 1.00
Elevated 222 (216) 1.69 (1.37–2.09) <0.001 127 (122) 1.88 (1.37–2.57) <0.001
BRAF
Wild-type 352 (323) 1.00 195 (171) 1.00
Mutated 92 (90) 1.72 (1.36–2.18) <0.001 43 (43) 2.17 (1.48–3.19) <0.001
CEA μg/l
Normal 5 68 (57) 1.00 64 (53) 1.00
Elevated > 5 183 (170) 1.44 (1.07–1.95) 0.017 174 (161) 1.80 (1.28–2.51) 0.001
Secondary curative surgery
Yes 35 (16) 1.00 26 (10) 1.00
No 419 (407) 6.74 (4.06–11.21) <0.001 212 (204) 4.97 (2.53–9.76) <0.001
First line chemotherapy
Oxaliplatin based 166 (142) 1.00 116 (97) 1.00
Irinotecan based 60 (58) 1.32 (0.97–1.79) 0.078 31 (29) 0.88 (0.57–1.36) 0.571
Other or none 229 (224) 3.00 (2.42–3.73) <0.001 91 (88) 1.64 (1.05–2.57) 0.031
Nuclear RBM3 expression
Low 166 (164) 1.00 82 (81) 1.00
High 289 (260) 0.61 (0.50–0.74) <0.001 156 (133) 0.67 (0.50–0.90) 0.008
Continuous Nuclear RBM3 expression 455 (424) 0.74 (0.65–0.83) <0.001 238 (114) 0.77 (0.65–0.92) 0.005
Cytoplasmic RBM3 expression
Low 126 (124) 1.00 64 (63) 1.00
High 329 (300) 0.61 (0.49–0.76) <0.001 174 (151) 0.66 (0.48–0.91) 0.011
Continuous Cytoplasmic RBM3 expression 455 (424) 0.71 (0.61–0.84) <0.001 238 (114) 0.85 (0.68–1.07) 0.161
*The multivariable HRs for other variables than RBM3 are based on inclusion of nuclear RBM3 expression in the model.
https://doi.org/10.1371/journal.pone.0182512.t002
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significantly longer PFS in those treated with first-line oxaliplatin based chemotherapy com-
pared to those treated with first-line irinotecan based chemotherapy, although the actual sur-
vival gain was less then one month. The association of high RBM3 expression with OS has
previously not been studied in a cohort with only mCRC patients. Melling et al [23] evaluated
RBM3 expression in primary CRC (stages I-III), and found an association between high
Fig 3. Kaplan-Meier estimates of progression free (A-B) and overall survival (C-D). Estimates in
combined strata according to high and low RBM3 expression and type of treatment given as first-line. A and C
illustrate nuclear expression and B and D cytoplasmic expression. Log rank p-values correspond to pairwise
comparison of RBM3 and oxaliplatin treatment with the other strata.
https://doi.org/10.1371/journal.pone.0182512.g003
Table 3. Treatment and treatment response. Divided according to high and low nuclear RBM3 expression, and positive and negative nuclear RBM3
expression. (Regarding cytoplasmic expression see S3 Table).
Nuclear expression RBM3
All patients High expression Low expression p-value Positive Negative p-value
N(%) N (%) N (%) N (%) N (%)
All patients 455 289 (64) 166 (36) 409 (90) 46 (10)
1-line chemotherapy 283 (62) 175 (61) 108 (65) 0.292 255 (62) 28 (61) 0.845
1-line combination oxaliplatin 166 (36) 113 (39) 53 (71) 0.143 151 (30) 15 (32) 0.542
1-line combination irinotecan 57 (13) 42(15) 15 (9) 0.094 54 (13) 3 (7) 0.190
Response rate 1-line
CR/PR 103 (23) 76 (26) 27 (16) 0.015 94 (23) 9 (20) 0.114
PD 45 (10) 24 (8) 21(13) 37 (9) 8 (17)
PFS 1-line median in months 7.85 8.93 6.08 <0.001 7,95 6.60 0.319
2-line chemotherapy 163 (36) 118 (41) 45 (33) 0.004 148 (36) 15 (33) 0.624
Response rate 2-line
CR/PR 25 (5) 20 (7) 5 (3) 0.208 24 (6) 1 (2) 0.176
PD 56 (12) 37(13) 19 (11) 48 (12) 8 (17)
CR = complete response, PR = partial response, PD = progressive disease as best response, PFS = progression free survival
https://doi.org/10.1371/journal.pone.0182512.t003
RBM3 and metastatic colorectal cancer
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RBM3 expression and longer OS. Hjelm et al [19] studied two different cohorts and only 15%
of the patient had stage IV disease. They did however not see any correlation between RBM3
expression and disease stage. Of note, while previous studies in primary CRC found nuclear
RBM3 expression to be the strongest prognostic factor [19, 23], the results from the present
study demonstrate that not only nuclear, but also cytoplasmic RBM3 expression was signifi-
cantly associated with prolonged survival. These associations between high RBM3 expression
and prolonged oxaliplatin response are in line with previous findings in epithelial ovarian can-
cer, where a high RBM3 expression was associated with an improved prognosis, and silencing
of RBM3 in ovarian cancer cells led to a decreased sensitivity to cisplatin [16].
The optimal prognostic and/or predictive cutoff for RBM3 remains to be established, pref-
erably in prospective studies. Varying cutoffs have been used in previous studies, i.e. week ver-
sus strong in the paper by Melling and al[23] and negative versus positive in the paper by
Hjelm et al[19]. Our analyses are based on both CRT analyses, and positive versus negative
expression, with similar prognostic value, although the former was more significant. The CRT
based cutoff appears to well in line with the cutoff used in the study by Melling et al[23].
High nuclear and high cytoplasmic RBM3 expression were associated with BRAF wild type,
secondary surgery and irinotecan based treatment. Positive expression, in comparison to nega-
tive expression, was related to rectal tumours and BRAF wild type regarding nuclear expres-
sion and BRAF wild type and secondary surgery regarding cytoplasmic expression. The
association of high RBM3 expression with BRAF wild type tumours is in accordance with ear-
lier reports. Yokota et al [28] among others, have shown that BRAF mutation is associated
with shorter OS, which has also been shown in this cohort [25]. Of note, the frequency of
BRAF mutation in this cohort is higher compared to prior reports probably due to the non-
selected cohort, whereas other reported rates of BRAF mutation often refer to groups that have
been included in a clinical trial [25]. The finding of RBM3 expression being significantly
higher in cases that had undergone secondary surgery further underpins its association with a
less aggressive tumour phenotype, since secondary surgery is relevant when the metastatic bur-
den is limited and the metastases are resectable upfront or after conversion chemotherapy.
All tumours in the herein examined cohort are derived from patients with unresectable
mCRC, a group of patients who often have a limited survival. Nevertheless, even in this patient
category, high RBM3 expression was demonstrated to be an independent factor of a prolonged
survival. It must however be pointed out that the tumour samples examined in this study were
mainly obtained from the primary tumours. Moreover, there were no paired specimens from
primary tumours and metastases. Therefore, we cannot draw any conclusions on the expres-
sion of RBM3 in the metastases, which may differ from the primary tumours. However, since
chemotherapy may alter the expression of biomarkers [29, 30], the survival analyses were also
performed after exclusion of patients who had received adjuvant chemotherapy, with similar
results. A few other studies have compared RBM3 expression in primary tumours and metasta-
ses. In malignant melanoma, Jonsson et al [17] reported that RBM3 expression was downregu-
lated in metastases as compared with primary tumours. In contrast, in oesophageal and gastric
adenocarcinoma, RBM3 expression was similar in primary tumours and lymph node metasta-
ses [22].
Considering this, the number of TMAs available (58%) must be considered adequate. It
could be discussed if TMA cores are representative of the whole tumour. To adjust for hetero-
geneity issues, duplicate 1 mm cores were obtained from different tumour areas. Furthermore,
the TMA technique is a good method to demonstrate the connection between molecular alter-
ations and clinical endpoints [31].
It is important to bear in mind that different physicians selected treatment for their patients
and we can only speculate on the rationale for selecting a certain treatment. Irinotecan based
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treatment were, for example, initiated more often to patients that had metachronous disease.
However, the difference in OS, regarding both nuclear and cytoplasmic expression, remained
significant when adjuvant treated patients were excluded.
Palliative chemotherapy is a balance act between effects and side effects. Peripheral neurop-
athy is a common side effect of oxaliplatin treatment that may lead to considerable disability in
everyday life, for example leading to difficulties using a keyboard or buttoning a shirt. Since
the effect of oxaliplatin appears to be limited in patients with tumours displaying low RBM3
expression, several patients could be spared suffering, at least temporarily, if another agent is
given in first-line.
In summary, the results demonstrate that high RBM3 expression is associated with pro-
longed survival in patients with mCRC, in particular in those having received first-line oxali-
platin based chemotherapy. These findings merit further study, since they are of potential
clinical relevance. It would also be of interest to explore the impact of RBM3 expression on
oxaliplatin sensitivity in CRC cells in vitro.
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